7xm app login for android
7xm app login for android
Simon Ekpa: PDP chief reacts as Finland detains Biafran separatist, makes key demand from Tinubu
Stocks fell for a second day this week as investors brace for Wednesday's CPI report. An inflation surprise could sway the Fed's interest rate decision next week. Google rose as much as 6% after unveiling a quantum computing breakthrough. The year-end rally wavered for a second day this week, with major US indexes slipping through Tuesday's session. The Dow Jones Industrial Average lost over 150 points, and the S&P 500 and the Nasdaq Composite also dropped. A Chinese probe into Nvidia pulled equities lower in Monday's session. On Tuesday, investors held off on major market bets, with attention focused on the coming consumer price index report for November. The print will be published Wednesday morning, and could sway the Federal Reserve's interest rate decision next week. Economists expected prices to have risen 2.7% on an annual basis, slightly higher than October's 2.6% increase. A hotter reading than expected could shake markets , Bank of America said this week, given that the options traders are predicting the smallest CPI-related move in three years. This report will help dictate the Fed's next policy decision at its meeting on December 17-18. Markets are eyeing an 86% chance the central bank will lower rates by a quarter-point, though any inflation surprise could upend the market's predictions. Among individual stocks, Alphabet was a winner on Tuesday. The Google-parent jumped as much as 6% after revealing a quantum computing breakthrough . Oracle shed about nearly 7% after a disappointing second-quarter earnings report. Meanwhile, shares of UnitedHealth Group have slumped 10% since last week's fatal shooting of CEO Brian Thompson. Here's where US indexes stood at the 4:00 p.m. bell on Tuesday: S&P 500 : 6,034.91, down 0.30% Dow Jones Industrial Average : 44,247.83, down 0.35% (-154.10 points) Nasdaq composite : 19,687.24, down 0.25% Here's what else happened today: Bitcoin's pullback after rising above $100,000 creates 13% correction risk , chart master says. World governments need to slash spending or risk being 'too late' when markets panic , BIS says. The market's blistering postelection rally has some ringing alarms for 2025 . A 'silver tsunami' of boomer home sales won't fix housing affordability , Zillow says. Watch Japan as a key source of market risk next year, a research firm says. In commodities, bonds, and crypto: West Texas Intermediate crude oil stayed essentially flat at $68.36 a barrel. Brent crude , the international benchmark, fell by o.22% to $71.99 a barrel. Gold rose 1.2% to $2,718 an ounce. The 10-year Treasury yield increased two basis points to 4.222%. Bitcoin slid 0.3% to $96,343.14.
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced that it intends to offer to sell common shares and warrants in an underwritten public offering. All of the common shares and warrants are to be sold by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. ThinkEquity is acting as the sole book-running manager for the offering. The Company intends to use the net proceeds from the offering primarily for working capital requirements, general corporate purposes, and the advancement of business objectives. The securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-276650), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 22, 2024 and declared effective on January 31, 2024. The offering will be made only by means of a written prospectus. A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering has been or will be filed with the SEC on its website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from the offices of ThinkEquity, 17 State Street, 41 st Floor, New York, New York 10004. Before investing in this offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. About BriaCell Therapeutics Corp. BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/ . Forward-Looking Statements This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those related to our ability to close the underwritten public offering and the use of proceeds, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risk Factors” in the Company’s most recent annual report, and in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law. Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release. Company Contact: William V. Williams, MD President & CEO 1-888-485-6340 info@briacell.com Media Relations: Jules Abraham CORE IR julesa@coreir.com Investor Relations Contact: CORE IR investors@briacell.comHow to Watch Top 25 Women’s College Basketball Games – Saturday, November 23Nick Kyrgios makes fresh attack on Jannik Sinner as the Italian’s doping scandal rumbles on
Smart Lawn Mowers Market 2024 Size, Share, Growth Report 2032
